Immunitybio Net Worth
Immunitybio Net Worth Breakdown | IBRX |
Immunitybio Net Worth Analysis
Immunitybio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immunitybio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immunitybio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immunitybio's net worth analysis. One common approach is to calculate Immunitybio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immunitybio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immunitybio's net worth. This approach calculates the present value of Immunitybio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immunitybio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immunitybio's net worth. This involves comparing Immunitybio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immunitybio's net worth relative to its peers.
Enterprise Value |
|
To determine if Immunitybio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunitybio's net worth research are outlined below:
| Immunitybio had very high historical volatility over the last 90 days | |
| Immunitybio has a very high chance of going through financial distress in the upcoming years | |
| Immunitybio currently holds 504.17 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 14.74 M. Net Loss for the year was (413.64 M) with profit before overhead, payroll, taxes, and interest of 31.16 M. | |
| Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company |
Immunitybio Quarterly Good Will |
|
Immunitybio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunitybio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunitybio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Immunitybio Target Price Consensus
Immunitybio target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Immunitybio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Immunitybio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Immunitybio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Immunitybio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationImmunitybio Target Price Projection
Immunitybio's current and average target prices are 2.75 and 11.40, respectively. The current price of Immunitybio is the price at which Immunitybio is currently trading. On the other hand, Immunitybio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Immunitybio Target Price
Know Immunitybio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunitybio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunitybio backward and forwards among themselves. Immunitybio's institutional investor refers to the entity that pools money to purchase Immunitybio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Charles Schwab Investment Management Inc | 2025-03-31 | 1.3 M | Goldman Sachs Group Inc | 2025-03-31 | 1.1 M | Jpmorgan Chase & Co | 2025-03-31 | 1 M | Bsc Private Wealth Management, Llc | 2025-03-31 | 846.4 K | Verition Fund Managegment, Llc | 2025-03-31 | 827 K | Susquehanna International Group, Llp | 2025-03-31 | 773.5 K | Allen Holding Inc | 2025-03-31 | 687.6 K | Sheets Smith Wealth Management | 2025-03-31 | 633.5 K | Accurate Wealth Management, Llc | 2025-03-31 | 560 K | Vanguard Group Inc | 2025-03-31 | 20.3 M | Blackrock Inc | 2025-03-31 | 13.3 M |
Follow Immunitybio's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.43 B.Market Cap |
|
Project Immunitybio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.13) | (1.18) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (1.08) | (1.13) | |
| Return On Equity | 0.85 | 0.89 |
When accessing Immunitybio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immunitybio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunitybio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immunitybio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunitybio. Check Immunitybio's Beneish M Score to see the likelihood of Immunitybio's management manipulating its earnings.
Evaluate Immunitybio's management efficiency
Immunitybio has return on total asset (ROA) of (0.5562) % which means that it has lost $0.5562 on every $100 spent on assets. This is way below average. Immunitybio's management efficiency ratios could be used to measure how well Immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.89 in 2025, whereas Return On Tangible Assets are likely to drop (1.18) in 2025. At this time, Immunitybio's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 25 M in 2025, whereas Total Assets are likely to drop slightly above 299.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.70) | (0.67) | |
| Tangible Book Value Per Share | (0.72) | (0.69) | |
| Enterprise Value Over EBITDA | (8.88) | (9.32) | |
| Price Book Value Ratio | (3.66) | (3.47) | |
| Enterprise Value Multiple | (8.88) | (9.32) | |
| Price Fair Value | (3.66) | (3.47) | |
| Enterprise Value | 3.5 B | 2.8 B |
The strategic initiatives led by Immunitybio's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunitybio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunitybio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunitybio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunitybio time-series forecasting models is one of many Immunitybio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunitybio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immunitybio Earnings per Share Projection vs Actual
Immunitybio Corporate Management
| Jason JD | General Secretary | Profile | |
| Sandeep MD | Chief Officer | Profile | |
| Helen Luu | Chief Officer | Profile | |
| Leonard MD | Chief Officer | Profile | |
| Jason Liljestrom | General Secretary | Profile | |
| Bruce MD | Senior Affairs | Profile |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.